No Data
No Data
No Data
No Data
No Data
Ocular Therapeutix To Present at Two Ophthalmology Meetings, May 4-9, 2024
BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")), a biopharmaceutical company committed to enhancing people's vision and quality of life through the
GlobeNewswireMay 3 19:30
Ocular Therapeutix Currently Down Nine Consecutive Days, On Pace for Longest Losing Streak Since October 2019 -- Data Talk
Ocular Therapeutix Inc. (OCUL) is currently at $4.75, down $0.25 or 5% --Would be lowest close since Jan. 26, 2024, when it closed at $4.66 --Currently down 10 of the past 11 days --Currently down
Dow JonesApr 24 23:18
Optimistic Buy Rating for Ocular Therapeutix Amid Early-Stage NPDR Study and Wet AMD Potential
TipRanksApr 22 13:46
Baird Sees Weakness in Ocular Shares "Overdone" in Wake of Phase 1 Data
Seeking AlphaApr 20 06:07
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Super Micro Computer, Inc. (NASDAQ:SMCI) fell sharply during Friday's session.The company announced its third-quarter earnings date and did not provide preliminary estimates as it did with t
BenzingaApr 20 01:25
HC Wainwright & Co. : The Ocular Therapeutix (OCUL.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $16.00.
HC Wainwright & Co. : The Ocular Therapeutix (OCUL.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $16.00.
Zhitong FinanceApr 19 18:30
No Data
No Data